Mr. Stephan Jackman, Chief Executive Officer of Alzamend Neuro, with over twenty years of multi-industry experience in administration, business and product development, marketing, project and program management, and strategic planning, provides a dynamic blend of bio-pharma experience and corporate leadership to navigate the challenges commonly faced by a developmental biotech company. He has played an intricate role in the development of therapeutic treatments, products and programs from the research stage to market and commercialization with the dual focus of creating value for internal and external stakeholders while developing strategic alliances and cross-function teams to meet and exceed goals.
Mr. Jackman has held positions of increasing responsibility at Novartis Pharmaceuticals Corporation, L’Oreal USA, SBM Management Services, and Family Intervention Services. Prior to joining Alzamend Neuro, Mr. Jackman was the Chief Operating Officer of Ennaid Therapeutics, an emerging bio-pharmaceutical focusing on cures for mosquito borne infectious diseases, such as Zika and Dengue viruses. Additionally, he has been an independent project and management consultant assisting start-ups, Fortune 500 companies and non-profits with major strategic initiatives.
A champion of diversity and inclusion, Mr. Jackman has developed and led multiple affinity groups at previous organizations and has represented several organizations by serving on multiple non-profits board of directors. Additionally, Mr. Jackman is an advocate for K-12 STEM education having spent over fifteen years mentoring and teaching math to “at-risk” high school students in the Kean University Upward Bound program and Stevens Technical Enrichment Program. Mr. Jackman believes strongly in developing stronger bonds between business and community and eagerly has participated and driven socially responsible initiatives.
Mr. Jackman earned a Master of Science in Management and a Bachelor of Engineering in Mechanical Engineering from Stevens Institute of Technology.